Scientific Reports
March 5, 2018
Kai Zhang, Yuko Fujita, Kenji Hashimoto
Since the metabolism of (R,S)-ketamine to (2R,6R)-hydroxynorketamine (HNK) is reported to be essential for ketamine's antidepressant effects, there is an increasing debate about antidepressant effects of (2R,6R)-HNK. Using pharmacokinetic and behavioral techniques, we investigated whether intracerebroventricular (i.c.v.) infusion of (R)-ketamine or (2R,6R)-HNK show antidepressant effects in a...
The Gerontologist
March 2, 2018
Rebecca Collins, Naoko Kishita
101 citations
BACKGROUND AND OBJECTIVES: The application of mindfulness- and acceptance-based interventions (MABIs) for informal caregivers of people with dementia (PwD) is relatively novel, and the current state of the evidence base is unclear. This meta-analysis examined the effectiveness of MABIs on reducing symptoms of depression and burden in informal caregivers of PwD. The quality of included studies...
Journal of Clinical Psychology
March 2018
Tim Lomas, Juan Carlos Medina, Itai Ivtzan et al.
Among efforts to improve the well-being of healthcare professionals are initiatives based around mindfulness meditation. To understand the value of such initiatives, we conducted a systematic review of empirical studies pertaining to mindfulness in healthcare professionals. Databases were reviewed from the start of records to January 2016. Eligibility criteria included empirical analyses of...
Cannabis and Cannabinoid Research
March 1, 2018
Nadia Solowij, Samantha J Broyd, Camilla Beale et al.
Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to ameliorate cognitive, symptomatic, and brain harms in cannabis...
CNS Drugs
March 2018
Panos Zanos, Scott M. Thompson, Ronald S. Duman et al.
Traditional pharmacological treatments for depression have a delayed therapeutic onset, ranging from several weeks to months, and there is a high percentage of individuals who never respond to treatment. In contrast, ketamine produces rapid-onset antidepressant, anti-suicidal, and anti-anhedonic actions following a single administration to patients with depression. Proposed mechanisms of the...
Brain Research Bulletin
March 1, 2018
The-Vinh Tran, Se Jin Park, Eun-Joo Shin et al.
Accumulating evidence suggests that neuroinflammation is one of the important etiologic factors of abusive and neuropsychiatric disorders. Platelet-activating factor (PAF) is potent proinflammatory lipid mediat1or and plays a pivotal role in neuroinflammatory disorders through the specific PAF receptor (PAF-R). Phencyclidine (PCP) induces a psychotomimetic state that closely resembles...
SHILAP Revista de lepidopterología
March 1, 2018
Elaheh Mahmoudi, Mehrdad Faizi, Reza Hajiaghaee et al.
14 citations
Background and objectives: Considering the increasing prevalence of depression, many studies are launched to investigate new antidepressant treatments. The present research has shown how psilocybin as an active compound of Psilocybe cubensis (Earle) Singer extract (PCE) can change the parameters related to depression and anxiety in animal models. Both serotonin (5-hydroxytryptamine: 5-HT) and...
Molecular Psychiatry
February 27, 2018
Allison C. Nugent, Elizabeth D. Ballard, T. Gould et al.
254 citations
Ketamine’s mechanism of action was assessed using gamma power from magnetoencephalography (MEG) as a proxy measure for homeostatic balance in 35 unmedicated subjects with major depressive disorder (MDD) and 25 healthy controls enrolled in a double-blind, placebo-controlled, randomized cross-over trial of 0.5 mg/kg ketamine. MDD subjects showed significant improvements in depressive symptoms,...
Revista Brasileira de Psiquiatria
February 24, 2018
Camila Bernardes, P. Mattos, B. P. Nazar
Rev Bras Psiquiatr. 2018;40:110 Brazilian Journal of Psychiatry 00000000-0002-7316-1185 | doi:10.1590/1516-4446-2017-2380 Singh et al. reported that two or three weekly 40 min i.v. infusions of ketamine (0.5 mg/kg) are safe and effective for maintaining an acute response to ketamine during one month of treatment for resistant depression (TRD). We present herein the results of an open label...
Biological Psychiatry
February 23, 2018
Alessia Mastrodonato, Randy Martinez, Ina P. Pavlova et al.
BACKGROUND We previously reported that a single injection of ketamine prior to stress protects against the onset of depressive-like behavior and attenuates learned fear. However, the molecular pathways and brain circuits underlying ketamine-induced stress resilience are still largely unknown. METHODS Here, we tested if prophylactic ketamine administration altered neural activity in the...